Approximately 6,600 individuals in England diagnosed with a serious heart condition will soon have access to a new treatment following the simultaneous approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE).
Aficamten: A New Hope for HCM Patients
Aficamten, marketed under the name MYQORZO, is a daily oral medication designed for individuals suffering from obstructive hypertrophic cardiomyopathy (HCM). This condition is characterised by the thickening and stiffening of the heart muscle, which significantly hampers the heart’s ability to pump blood efficiently. Symptoms of HCM can include severe fatigue, dizziness, shortness of breath, chest pain, and arrhythmias. Approximately one in every 500 people in the UK is affected by HCM, with around half of the cases being hereditary.
Clinical trial results indicate that aficamten enhances patients’ ability to engage in physical activity and alleviates their symptoms. Preliminary assessments suggest that its efficacy is comparable to mavacamten, the other NICE-approved treatment for HCM, with the added benefit of potentially requiring fewer monitoring scans to determine the appropriate dosage.
Streamlined Access to Innovative Treatments
NICE adopted a cost comparison approach to evaluate aficamten, necessitating that the manufacturer demonstrate that its costs are on par with or lower than those of mavacamten for treating symptomatic HCM, which is already recommended by NICE and in use within the NHS.
In a notable advancement, NICE published its final guidance two weeks ahead of its usual timeline, thanks to improved collaboration with the MHRA. Following reforms implemented through its transformation programme, NICE is now able to publish guidance for medications 30% faster and for health technologies 9% faster than prior to April 2024.
Voices from the Health Sector
Helen Knight, the Director of Medicines Evaluation at NICE, expressed her satisfaction with the approval, stating, “We’re pleased to be able to recommend a treatment that has the potential to alter the course of obstructive hypertrophic cardiomyopathy and offers new hope to people with this serious condition. This treatment being approved demonstrates the value of closer working between NICE and the MHRA, ensuring that safe, effective medicines get to people earlier by aligning licensing and value assessment decisions.”
Julian Beach, the MHRA’s Executive Director of Healthcare Quality and Access, highlighted the significance of this dual approval, remarking, “Today’s authorisation of aficamten, alongside NICE’s publication of final guidance, marks an important milestone for patients with obstructive hypertrophic cardiomyopathy and for the UK’s medicines regulatory system. This demonstrates how closer working can help patients access innovative treatments sooner, while maintaining the robust standards of safety, quality, and effectiveness that patients rightly expect.”
Patient Perspectives and Potential Impact
Katherine McIntosh, CEO of Cardiomyopathy UK, expressed delight at the availability of aficamten for individuals living with obstructive HCM. She noted, “As part of the NICE appraisal, we submitted insights from our patient community, including the impact of symptoms, experiences of NHS treatment and care, and what another treatment option could mean. Having an additional option is very welcome. This outcome means greater choice for patients and the opportunity for more people living with obstructive HCM to benefit from treatment, feel better, and live well.”
Understanding Aficamten’s Mechanism
Aficamten’s active component is a reversible cardiac myosin inhibitor that binds to the myosin protein in heart muscle cells, thereby reducing excessive muscle contraction. This mechanism aids in facilitating smoother blood flow from the heart, consequently alleviating the symptoms associated with obstructive hypertrophic cardiomyopathy.
The medication is available in film-coated tablet form in strengths of 5 mg, 10 mg, 15 mg, and 20 mg. Ongoing monitoring of heart function, including regular echocardiograms, will be implemented for patients undergoing treatment to assess the health of their heart and ensure the safe administration of the drug.
Commitment to Ongoing Safety Review
As with any new medication, the MHRA will continue to closely monitor the safety and efficacy of aficamten. Patients experiencing potential side effects are encouraged to consult with their healthcare provider and report any concerns through the Yellow Card scheme, accessible via the MHRA website or mobile applications.
NHS England is set to make aficamten accessible within 30 days of NICE releasing its final guidance, having negotiated a confidential discount with the manufacturer to provide the medication at a reduced cost to the NHS.
For additional information regarding the final guidance for aficamten and its use in treating symptomatic obstructive hypertrophic cardiomyopathy, the NICE website offers comprehensive resources.
More Stories
Professor David Strain Takes the Helm as Chief Medical Advisor at the DWP
HM Land Registry Introduces Property Identifiers for Price Paid Data Starting 28th August
Housing Associations Focus on Enhancing Consumer Experience with Upgrades